BB Biotech Valuation
| BION Stock | CHF 45.95 0.50 1.10% |
At this time, the entity appears to be fairly valued. BB Biotech AG owns a latest Real Value of ₣45.77 per share. The recent price of the entity is ₣45.95. Our model approximates the value of BB Biotech AG from evaluating the entity fundamentals such as Shares Owned By Insiders of 0.07 %, return on asset of 0.0453, and Shares Outstanding of 55.15 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BB Biotech's valuation include:
Price Book 1.0984 | Enterprise Value | Enterprise Value Ebitda (0.12) | Price Sales 14.5018 | Trailing PE 13.5099 |
Fairly Valued
Today
Please note that BB Biotech's price fluctuation is very steady at this time. Calculation of the real value of BB Biotech AG is based on 3 months time horizon. Increasing BB Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BION stock is determined by what a typical buyer is willing to pay for full or partial control of BB Biotech AG. Since BB Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BION Stock. However, BB Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 45.95 | Real 45.77 | Hype 45.99 |
The intrinsic value of BB Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BB Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BB Biotech AG helps investors to forecast how BION stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BB Biotech more accurately as focusing exclusively on BB Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BB Biotech's intrinsic value based on its ongoing forecasts of BB Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BB Biotech's closest peers.
BB Biotech Cash |
|
BB Biotech Total Value Analysis
BB Biotech AG is currently anticipated to have takeover price of 2.2 B with market capitalization of 2.25 B, debt of 117.5 M, and cash on hands of 458 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BB Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.2 B | 2.25 B | 117.5 M | 458 K |
BB Biotech Investor Information
About 15.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.1. Some equities with similar Price to Book (P/B) outperform the market in the long run. BB Biotech AG last dividend was issued on the 21st of March 2025. The entity had 5:1 split on the 29th of March 2016. BB Biotech AG may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.BB Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BB Biotech has an asset utilization ratio of 4.64 percent. This indicates that the Company is making ₣0.0464 for each dollar of assets. An increasing asset utilization means that BB Biotech AG is more efficient with each dollar of assets it utilizes for everyday operations.BB Biotech Profitability Analysis
Considering the key profitability indicators obtained from BB Biotech's historical financial statements, BB Biotech AG is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess BB Biotech's ability to earn profits and add value for shareholders.Net Income | First Reported 2009-03-31 | Previous Quarter -240.9 M | Current Value -100.2 M | Quarterly Volatility 376 M |
For BB Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BB Biotech AG to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BB Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BB Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BB Biotech over time as well as its relative position and ranking within its peers.
BB Biotech Earnings per Share Projection vs Actual
By analyzing BB Biotech's earnings estimates, investors can diagnose different trends across BB Biotech's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for BB Biotech AG is based on EPS before non-recurring items and includes expenses related to employee stock options.BB Biotech Ownership Allocation
BB Biotech AG secures a total of 55.15 Million outstanding shares. Roughly 85.17 % of BB Biotech outstanding shares are held by general public with 0.07 percent owned by insiders and only 14.76 (percent) by institutions. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.BB Biotech Profitability Analysis
The company reported the revenue of 111.63 M. Net Income was 75.9 M with profit before overhead, payroll, taxes, and interest of 201.41 M.About BB Biotech Valuation
Our relative valuation model uses a comparative analysis of BB Biotech. We calculate exposure to BB Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BB Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 100.5 M | 175.1 M | |
| Pretax Profit Margin | 0.78 | 0.82 | |
| Operating Profit Margin | 0.87 | 0.91 | |
| Net Profit Margin | 0.78 | 0.82 | |
| Gross Profit Margin | 0.02 | 0.02 |
BB Biotech Quarterly Retained Earnings |
|
Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.